ClinicalTrials.gg
RecruitingNCT06314334Updated Apr 9, 2026

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

A Phase 2 interventional study of Sintilimab+Pegaspargase and P-GemOx in Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, sponsored by Fudan University. Recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Lymphoma, T-Cell with a site in China — 31 open to participants now, 34 under way, 4 of them phase 3. Lymphoma, T-Cell · China.

Planned enrollment
5th of 69
210 · median 38
Started
2024
with 7 others
Phase 2
25 of 75
13 open now
Primary completion
2026-12
later than 17 of 33 live
Registered
56th of 75
by date
Lead sponsor
4 of 75
Fudan University

Among the 75 studies in Lymphoma, T-Cell with a site in China, this one is the 5th largest by planned enrollment of the 69 interventional ones that give a count, is one of 8 that started in 2024, is one of 25 in phase 2, reaches primary completion later than 17 of the 33 other live ones, and was the 56th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

31 of the 75 studies in Lymphoma, T-Cell with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Lymphoma, T-Cell with a site in China, or all of them as a file.
02

Study summary

Extranodal NK/T-cell lymphoma, nasal type (NKTCL) is a common malignant tumor in East Asian populations, often starting in the nasal cavity and spreading to other organs. Associated with EBV infection, NKTCL is aggressive. Early-stage patients typically receive chemo and radiotherapy, with promising outcomes. Recent studies show the potential of immune checkpoint inhibitors in NKTCL treatment. However, optimal treatment sequencing and efficacy remain unclear. This study aims to compare three strategies: (A) Pegaspargase with Sintilimab and radiotherapy; (B) chemo then radiotherapy (PGemOx); (C) sandwich chemoradiotherapy (GELAD). The goal is to identify the best treatment based on 24-month progression-free survival.

Read the detailed description

Extranodal NK/T-cell lymphoma, nasal type (NKTCL) is a malignant hematological tumor that is common in East Asian populations. The disease typically manifests in the nasal cavity in its early stages and can later involve multiple organs throughout the body. Highly associated with EBV infection, NKTCL is known for its aggressive nature. Currently, early-stage patients usually undergo combined treatment with chemotherapy and radiotherapy. Recent studies have shown that combining chemotherapy and radiotherapy containing asparaginase can achieve a complete remission rate (CR) of over 80%, with long-term survival rates exceeding 70% for patients. In recent years, researchers have found that immune checkpoint inhibitors demonstrate high activity in NKTCL, becoming an important therapeutic option. However, it is worth noting that the optimal sequence of chemotherapy and radiotherapy, as well as the effectiveness of combining radiotherapy with immunotherapy, have not been defined. Studies on different treatment strategies have shown variations in treatment-related adverse reactions and compliance with regimens among patients. However, there is currently no prospective randomized controlled study comparing the efficacy and safety of different strategies. Therefore, it is necessary to identify a treatment strategy with good efficacy and tolerability for patients. This study will stratify early-stage NKTCL patients using the NRI scoring system and randomly assign them to three different treatment strategies: (A) asparaginase combined with Sintilimab and synchronous radiotherapy; (B) sequential chemotherapy (PGemOx) followed by radiotherapy ; (C) chemotherapy (GELAD) with sandwiched chemoradiotherapy, to identify the best or worst treatment strategy based on the 24-month progression-free survival rate.

03

Conditions studied

  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Browse trials for

Keywords

  • Chemotherapy
  • Radiation therapy
  • Immune checkpoint inhibitor
  • Pegaspargase
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who meet the diagnostic criteria for NKTCL (WHO-2016) based on pathological examination.
  • Primary lesions located in the upper respiratory and digestive tract such as the nasal cavity, sinuses, nasopharynx, oropharynx, or oral cavity, with clinical staging of IE/IIE based on PET/CT and bone marrow examination according to the Lugano 2014 criteria.
  • Evaluated for lymphoma response according to the Lugano 2014 criteria, with at least one or lesion assessable by PET/CT.
  • No prior treatment with chemotherapy, radiotherapy, immunotherapy, or biological therapy for lymphoma.
  • Age between 18 and 75 years, both genders.
  • performance status (ECOG) score of 0-2.
  • Must have adequate organ and bone marrow function, defined as follows:

Hematology: (ANC) ≥1.0×10\^9/L, count (PLT) ≥75×10\^9/L, (Hb) ≥90g/L; no administration of granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion in the previous 14 days.

Liver function: Total (TBIL) ≤1.5 times the (ULN); (ALT) and aspartate aminotransferase (AST) ≤2×ULN.

Renal function: Serum creatinine (Cr) ≤1.5×ULN. Coagulation function: Plasma fibrinogen ≥1.5g/L. Cardiac function: (LVEF) ≥50%, no acute myocardial infarction, arrhythmia, or atrioventricular conduction block of grade I or above on .

  • Willing to comply with the study protocol, follow-up plan, and laboratory and ancillary investigations.

Exclusion criteria

Exclusion Criteria:

  • Patients co-infected with , , or with plasma HBV-DNA >10\^3/ml.
  • Patients with a history of pancreatitis.
  • Patients with acute or systemic infections requiring intravenous antibiotic therapy.
  • Patients with severe complications such as hemophagocytic syndrome, DIC, etc.
  • Significant organ dysfunction: such as respiratory failure, chronic congestive heart failure with class ≥2, decompensated liver or renal dysfunction, uncontrolled hypertension and diabetes despite aggressive treatment, and cardiovascular thrombotic or hemorrhagic events in the past 6 months.
  • Patients with a history of diseases who are not suitable for treatment with .
  • Pregnant and lactating women.
  • Patients with psychiatric disorders.
  • Known allergies to drugs in the chemotherapy regimen.
  • Patients with concomitant other tumors requiring surgery or chemotherapy within the past 6 months.
  • Currently using other experimental drugs.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Group A (synchronous treatment group)

    Patients received 4 cycles of Sintilimab combined with pegaspargase therapy, with each cycle lasting 3 weeks, for a total of 4 cycles. Concurrently, they received radiotherapy treatment (IMRT, 50-56Gy, starting within 21 days after the first Sintilimab treatment).

    Drug: Sintilimab+Pegaspargase · Radiation: IMRT

  • Experimental
    Group B (sequential treatment group)

    Patients received 4 cycles of the PGEMOX regimen chemotherapy. Each cycle lasted 3 weeks, with sequential radiotherapy (IMRT, 50-56Gy) administered within 4 weeks after the last chemotherapy cycle.

    Drug: P-GemOx · Radiation: IMRT

  • Experimental
    Group C (sandwiched radiotherapy group)

    Patients received 2 cycles of the GELAD regimen chemotherapy initially, with each cycle lasting 3 weeks. After the second cycle of chemotherapy, radiotherapy (IMRT, 50-56Gy) was administered within 4 weeks. Following the completion of radiotherapy, they received an additional 2 cycles of the GELAD regimen chemotherapy.

    Drug: GELAD · Radiation: IMRT

Interventions

  • DrugSintilimab+Pegaspargase

    Drug pages: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PegaspargaseStudies of PegaspargasePegaspargase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. Sintilimab, 200mg intravenous drip, on day 1; 2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;

  • DrugP-GemOx

    1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular; 2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip; 3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip

  • DrugGELAD

    1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip; 2. etoposide 60mg/m\^2 on day 1-3, intravenous drip; 3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular; 4. dexamethasone 20mg on day 1-4, intravenous drip.

  • RadiationIMRT

    Intensity modulated radiotherapy (50-56Gy)

06

What researchers measure

Primary outcomes

  1. PFS24

    Rate of patients with 24-month progression-free survival

    Time frame: From date of randomization until the date of first documented progression, assessed up to 24 months by the Lugano 2014 response criteria.

Secondary outcomes

  1. ORR

    Overall response rate

    Time frame: response rate at 24th week

  2. OS

    Overall survival

    Time frame: From the time of patient randomization to the end of study, assessed up to 60 months

  3. EFS

    Event-free survival

    Time frame: From the time of patient randomization to the end of study, assessed up to 60 months

  4. TRAE

    Treatment-related adverse event related to the study drug or intervention

    Time frame: From the time of patient randomization to the end of study, assessed up to 60 months

07

Study locations

7 of 7 sites recruiting
  • Cancer Hospital of Fujian Province
    Fuzhou, Fujian 350003, China
    Recruiting
    • Jiesong Wang, MD · Contact349697291@qq.com · 0086591-83660063
    • Jiesong Wang, MD · Principal investigator
  • Nantong Cancer Hospital
    Nantong, Jiangsu 226006, China
    Recruiting
    • Xiaohong Xu, MD · Contactxhx107@163.com · 0086513-86712049
    • Xiaohong Xu, MD · Principal investigator
  • Shanghai Eye Ear Nose and Throat Hospital,Fudan University
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
    • Hao Ding, MD · Contacteentding@163.com · 008621-64377134
    • Hao Ding, MD · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200092, China
    Recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Recruiting
  • People's Hospital of Ningbo University
    Ningbo, Zhejiang, China
    Recruiting
    • Dong Chen, MD · Contactshanying0626@163.com · 0086574-87016888
    • Dong Chen, MD · Principal investigator
08

References and documents

Publications

  • Zhu Y, Tian S, Xu L, Ma Y, Zhang W, Wang L, Jin L, Liu C, Zhu C, Li Z, Hao S, Zhong H, Ding H, Tao R. GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study. Br J Haematol. 2022 Feb;196(4):939-946. doi: 10.1111/bjh.17960. Epub 2021 Nov 21. PubMed 34806163 ↗
  • Zhang Y, Ma S, Cai J, Yang Y, Jing H, Shuang Y, Peng Z, Li B, Liu P, Xia Z, Xia Y, Gao Y, Chen D, Lin J, Li Q, Xu S, Xu Q, Zhang H, Huang H, Cai Q. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Am J Hematol. 2021 Nov 1;96(11):1481-1490. doi: 10.1002/ajh.26335. Epub 2021 Sep 13. PubMed 34449095 ↗
  • Wang H, Wang L, Li C, Wuxiao Z, Chen G, Luo W, Lu Y. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. Oncologist. 2020 Nov;25(11):e1725-e1731. doi: 10.1634/theoncologist.2020-0144. Epub 2020 Jul 29. PubMed 32627928 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 56 non-industry phase 2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 110. This study's planned 33 months is below that.

Counting every sponsor, half of 66 studies reached it within 68 months; a quarter within 33 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 18, 2024
StartActual
Mar 4, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06314334
Lead sponsor
Fudan University
Responsible party
Rong Tao (Prof., Fudan University) — Principal investigator
First posted
Mar 18, 2024
Start date
Mar 4, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Apr 9, 2026

Study contacts

Rong Tao, MD
Contact
rtao@shca.org.cn
8621-64175590
Chuanxu Liu, MD
Contact
liuchuanxu@shca.org.cn
021-64175590
Rong Tao, MD
study chair · Fudan Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sintilimab · Pegaspargase

Start the discussion